

TNF- α levels and presence of SNP-308G/A of TNF- α gene in temporomandibular disorder patients

Camilla Porto **CAMPELLO**^{1,3}

 <https://orcid.org/0000-0001-6689-5466>

Elker Lene Santos de **LIMA**^{2,3}

 <https://orcid.org/0000-0002-7171-7418>

Renata Silva Melo **FERNANDES**⁴

 <https://orcid.org/0000-0002-4886-5527>

Mirza **PORTO**⁵

 <https://orcid.org/0000-0002-6769-5324>

Maria Tereza Cartaxo **MUNIZ**^{3,6} 

 <https://orcid.org/0000-0001-9498-5223>

Submitted: May 06, 2020 • Revised and accepted: January 11, 2021

 tereza.cartaxo@upe.br

How to cite: Campello CP, Lima ELS, Fernandes RSM, Porto M, Muniz MTC. TNF- α levels and presence of SNP-308G/A of TNF- α gene in temporomandibular disorder patients. Dental Press J Orthod. 2022;27(1):e2220159.

(1) Universidade Federal Rural de Pernambuco, Programa de Pós-Graduação em Biotecnologia, Rede Nordeste de Biotecnologia (Recife/PE, Brazil). (2) Universidade de Pernambuco, Faculdade de Ciências Médicas, Programa de Pós-Graduação em Ciências da Saúde (Recife/PE, Brazil). (3) Universidade de Pernambuco, Hospital Universitário Oswaldo Cruz, Laboratório de Biologia Molecular-CEONHPE (Recife/PE, Brazil). (4) Universidade Federal de Pernambuco, Departamento de Prótese e Cirurgia Buco-Facial (Recife/PE, Brazil). (5) Universidade Católica de Pernambuco, Assessoria de Treinamento, Estágio, Pesquisa e Integração – ASTEPI (Recife/PE, Brazil). (6) Universidade de Pernambuco, Instituto de Ciências Biológicas (Recife/PE, Brazil).

ABSTRACT

Introduction: Temporomandibular disorder (TMD) refers to a group of conditions that compromise the harmonious movement and function of the temporomandibular joint, masticatory muscles, and associated structures. The etiopathogenesis of TMD is multifactorial but not well-understood, with the role of genetic factors still being unclear.

Objective: This review aims to summarize the results of studies that evaluated TNF- α levels and the -308G/A TNF- α polymorphism in TMD patients. This study emphasizes the importance of a more selective treatment involving TNF- α inhibitors that can potentially reduce inflammation and pain, and improve quality of life.

Methods: The MEDLINE/PubMed database, Cochrane Library, and Web of Science database were searched for case-control studies published until September 2020 that compared levels of TNF- α or presence of its -308G/A polymorphism in TMD patients and healthy individuals.

Results: Six case-control studies were identified with a total of 398 TMD patients, aged between 12 and 78 years. The control group consisted of 149 subjects, aged between 18 and 47 years. The occurrence of TMD was predominant in females. Majority of studies found high TNF- α levels in TMD patients, compared to the control group. One of these studies found a positive correlation between the GA genotype and the development of TMD.

Conclusion: Majority of the TMD patients showed elevated TNF- α levels, and a possible explanation for this could be the presence of the -308G/A polymorphism.

Keywords: Temporomandibular disorder. Interleukin. Polymorphism.

INTRODUCTION

Temporomandibular disorder (TMD) refers to a group of conditions that compromise the harmonious movement and function of the temporomandibular joint (TMJ), masticatory muscles, and associated structures.¹ Chronic TMD commonly occurs as orofacial pain, and is considered a public health problem.² It occurs more frequently and severely in women than in men.³ Its prevalence in the Brazilian population is between 4% and 12%.⁴ The most common symptoms of TMD are limited mandibular movements, TMJ sounds (click and crepitus), headache, and pain.⁵

The etiopathogenesis of TMD is multifactorial and involves joint and muscle trauma, anatomical factors, psychosocial aspects, and sensitization of nociceptive pathways, but the role of genetic factors in the etiology of TMD remains unclear and needs to be investigated.⁶ As TMD is caused by multiple factors, several forms of treatment are available, such as occlusal splints, counseling, physical therapy,⁷ surgery, acupuncture, botulinum toxin injection, pharmacotherapy,⁸ orofacial myofunctional therapy, and low laser therapy.⁹ Pharmacotherapy involves anti-inflammatory agents, analgesics, muscle relaxants, and in certain situations, tricyclic antidepressants; however, in certain cases, these therapeutics are not successful and patients suffer with persistent pain.⁸

In recent decades, a considerable amount of research data has accumulated in the field of TMD, and therapeutic techniques have also improved remarkably. Despite all the new information and alternative therapies that have come to light,¹⁰ there is no effective therapy in some cases, and patients are forced to suffer prolonged debilitating pain and have a poor quality of life. Thus, it is crucial to investigate the relationship between the genetic profile and development of TMD⁴, because it can help develop new therapeutic methods. Therefore, it is essential to monitor interleukin concentrations and identify gene polymorphisms that can modify interleukins levels.

Tumor necrosis factor alpha (TNF- α) is an important pro-inflammatory cytokine that contributes considerably to inflammation and immune response.¹¹ TNF- α is mainly produced by macrophages, lymphocytes, and trophoblastic cells.¹² The single nucleotide polymorphism (SNP) -308G/A TNF- α rs1800629 is characterized by the replacement of guanine (G) with adenine (A) in the promoter region of the gene, which leads to a greater production of this interleukin.¹³

Only a few studies have evaluated the presence of interleukins and genetic polymorphisms in TMD patients, but they have provided important results regarding the role of tumor necrosis factor. This has pointed to the possibility of the inclusion of this immune-inflammatory marker of immunity in the evaluation of

TMD, as well as in the development of a more selective treatment based on monoclonal antibodies.¹⁴ This review aims to summarize the results of studies that evaluated TNF- α levels and the -308G/A TNF- α polymorphism in TMD patients. These studies lead us to reflect on the importance of a more selective treatment involving TNF- α inhibitors that can potentially reduce inflammation and pain, and improve quality of life.

MATERIAL AND METHODS

ELIGIBILITY CRITERIA

Only those case-control studies that evaluated levels of TNF- α or its -308G/A polymorphism in TMD patients were included. Studies focusing on other polymorphisms and/or interleukins, and studies that did not draw comparison to a control group were excluded.

INFORMATION SOURCES AND SEARCH STRATEGY

The MEDLINE/PubMed database, Cochrane Library, and Web of Science database were searched for case-control studies published until September 2020 that compared TNF- α concentrations and presence of its -308G/A polymorphism in TMD patients and healthy controls. The following search terms were used for this purpose: "Temporomandibular Joint disorders Interleukin", "Temporomandibular Joint Disorders Polymorphism", "Temporomandibular Dysfunction Interleukin," and "Temporomandibular Dysfunction Polymorphism."

Furthermore, OpenGrey (www.opengrey.eu) was used for gray literature research. The studies were selected on the basis of their titles and summaries.

DATA COLLECTION PROCESS

The following variables were collected: author, type of study, number of patients, number of healthy individuals, gender, mean age, TNF- α levels, and the presence of the -308G/A polymorphism of this interleukin.

RESULTS

All reports considered in this review are case-control studies that measured TNF- α concentrations or detected the presence of -308G/A polymorphism in TMD patients. Six studies were identified, with a total of 398 TMD patients, aged between 12 and 78 years, whereas the control group consisted of 149 subjects, aged between 18 and 47 years. Details of the six studies included in this review are described in Table 1.

Table 1: Profile of TMD patients and healthy controls.

	Study, year	(n)		Gender		Age (years)	
		Patients	Controls	Patients	Controls	Patients	Controls
TMD TNF- α levels	Takahashi et al. ¹⁵ , 1998	51	6	46 females	0 females	17-78	27-39
		62 TMJ	10 TMJ	5 males	6 males		
	Kaneyama et al. ¹⁶ , 2002	117	7	123 females	0 females	12-74	27-35
		121 TMJ	9 TMJ	14 males	7 males		
	Lee et al. ¹⁷ , 2010	24	5	Not informed	Not informed	Not informed	Not informed
24 TMJ		5 TMJ					
Park, Chung ¹⁸ , 2016	40	20	40 females 0 male	20 females 0 males	32.9 \pm 13.3	32.9 \pm 13.3	
Louca Jounger et al. ¹⁹ , 2017	20	20	20 females 0 male	20 females 0 male	Above 18	Above 18	
TMD SNP	Furquim et al. ²⁰ , 2016	152	91	136 females 14 males	82 females 9 males	36.07 \pm 11.00	34.68 \pm 11.47

n = number, TMJ = temporomandibular joint.

Most patients in these studies were diagnosed according to the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD).²¹ Five studies evaluated TNF- α levels in TMD patients,¹⁵⁻¹⁹ which were expressed as mean concentration \pm SD (Table 2), and one study detected the presence of the -308G/A polymorphism of this interleukin²⁰ (Table 3). Most of these studies found higher TNF- α levels in the TMD patients group than in the healthy individuals.^{16,18-19}

Table 2: TNF- α levels in TMD patients and control group.

Studies	Diagnostic criteria	Diagnostic (n)	Sample type	Patients	Controls	p -value
Takahashi et al. ¹⁵	Reciprocal click in the joint, joint pain and short-term intermittent block for DD with click. TMJ block, impairment of joint mobility, joint pain and history of intermittent clicks and blocks for intermittent disc displacement. Impaired joint mobility, joint pain and bone degenerative changes in the joint surface observed in tomography and magnetic resonance for TMJ-OA	DD with click (8) DD with locking (25) TMJ-OA (18)	Synovial fluid	Detected in 5 joints	Not detected	>0.05
Kaneyama et al. ¹⁶	The same of Takahashi et al. ¹⁵	DD with click (8) DD with locking (54) TMJ-OA (59)	Synovial fluid	0.03 pg / mL DD with click; 0.17 pg / mL DD with locking; 0.17 pg / mL TMJ-OA	Not detected	<0.05
Lee et al. ¹⁷	Pain, mouth opening limitation and clicking	TMD acute pain (14) TMD chronic pain (10)	Synovial fluid	0.39 \pm 0.05 pg/mL	0.36 \pm 0.03pg/L	0.05
*Park, Chung ¹⁸	RDC/TMD ²¹	Greater disability (20) Lesser disability (20)	Plasma	4.55 pg / mL Greater disability; 1.86 pg / mL Lesser disability	0.11 pg / mL	\leq 0.001
#Louca Jounger et al. ¹⁹	RDC/TMD ²¹	TMD Myalgia (20)	Masseter muscle	10 pg / mL After repetitive dental tightening	3.5 pg / mL After repetitive dental tightening	0.042

n = number of patients, P = χ^2 , * Kruskal-Wallis test, # U test, DD = disc displacement, TMJ-OA = TMJ osteoarthritis, RDC/TMD = Research Diagnostic Criteria for Temporomandibular Disorders.

Table 3: Genotype distribution of the -308G/A SNP in patients and controls.

Study	Diagnostic criteria	Diagnostic (n)	Sample type	Patients genotype	Controls genotype	P	OR genotype GA	P ^o
Furquim et al. ²⁰	RDC/TMD ²¹	TMD (152)	Synovial fluid	GG - GA - AA 111 - 32 - 9	GG - GA - AA 79 - 8 - 4	<0.05	2.873	0.0116

P= X², OR=Odds ratio, P^o= P (OR).

DISCUSSION

This literature review included six articles that analyzed TNF- α levels or the -308G/A polymorphism in TMD patients, and compared their results with those of a control group. A total of 398 patients were evaluated, consisting of 346 females and 28 males, aged between 12 and 78 years. Age and gender of 24 of these patients were not specified. The prevalence of this disorder in females and in similar age groups has also been reported in other studies.^{4,9,22,23}

Of the six studies analyzed, five evaluated TNF- α concentrations and one investigated the presence of the -308G/A polymorphism, which is a G to A mutation at the -308 position in the promoter region, and is associated with higher levels of TNF- α .¹³ Despite the fact that these studies are difficult to compare because different fluids were used to measure the concentration of this interleukin, all lead us to reflect on the possibility of developing a more targeted treatment. Two articles^{16,18} found a significant difference in TNF- α levels of patients compared to

controls, which indicated that anti-TNF drugs may be prescribed for these patients. The first investigation¹⁶ illustrated that TNF- α concentration levels in patients with TMD disc displacement with locking (54) and TMJ-osteoarthritis (59) were greater than those in patients with TMD disc displacement with click (8). Nevertheless, there is a significant difference between the sample sizes of the TMD subgroups. Park and Chung¹⁸ found elevated TNF- α levels in a group with greater TMD disability (20) in comparison to a group with lesser disability (20), indicating that this interleukin level is higher in patients with greater disability.

Furquim et al.²⁰ identified that the GA genotype of the -308G/A polymorphism was significantly greater in patients than in controls. These findings could explain the elevated concentrations of this interleukin in patients evaluated by Kaneyama et al.,¹⁸ because the GA genotype is associated with an intermediate production of TNF- α , and the GG genotype is related to a low production of this interleukin.²⁴ Further experimental studies evaluating this polymorphism and TNF- α levels are required to confirm these results.

Louca Junger et al.¹⁹ evaluated TNF- α concentrations in masseter muscle and detected an increased concentration of this interleukin in patients compared to controls when measured after 160 min of evaluation and repetitive dental tightening. This data illustrates a patient's predisposition to a greater

production of TNF- α , and a possible reason for this could be the presence of the -308G/A polymorphism in TMD patients.

Similarly, Lee et al.¹⁷ found higher TNF- α levels in patients than in controls; however, there was no statistical difference between these groups ($p = 0.05$). This study had fewer patients (24) compared to other studies that measured TNF- α levels in synovial fluid. The sample size of the patients may have influenced the results. Additionally, this study included cases with acute and chronic pain; however, there was no statistically significant difference in TNF- α levels between these groups.

Takahashi et al.¹⁵ did not detect any difference in TNF- α levels between patients and healthy subjects. In this study, the patients had been treated for three months, which could have reduced inflammation and consequently the levels of interleukins. Medications were suspended at least two weeks prior to the synovial fluid collection; however, the treatment may have already helped to control the inflammation. In addition, patients were using an occlusal splint and undergoing physiotherapy, which can also decrease inflammation. There is a possibility that these treatments could have influenced the results. Furthermore, the control group only comprised men.

A recent study in transgenic mice observed that high concentrations of TNF- α cause catabolic changes that considerably affect the TMJ, causing irregular bone erosion and loss of cartilage.²⁵ The SNP -308G/A in the promoter region¹³ is associated with higher levels of TNF- α .²⁴ The A allele and AA genotype of the SNP -308G/A are associated with an increase in TNF- α production.^{13,24} Five studies described in this review analyzed TNF- α levels, and one evaluated the presence of the SNP -308G/A TNF- α . It is paramount to focus research efforts towards comparing TNF- α levels and its -308G/A polymorphism in the same patients.

Identifying inflammatory cytokines involved in TMD can help establish an innovative therapy or the development of new drugs.²⁶ Genetic polymorphisms can provide relevant information about an individual's health status, the risk of development of TMD or its severity, and specific treatment options.²⁷ TNF- α inhibitors reduce the risk of joint damage, improve physical function, and consequently, the quality of life of patients with rheumatoid arthritis,²⁸ an autoimmune disease that causes chronic pain and joint pain, including TMJ.²⁹ New investigations on these medications could also have significant therapeutic value in individuals with TMD.

Further research is required not only to measure TNF- α concentrations and identify the -308G/A TNF- α polymorphism, but also to detect other interleukins and polymorphisms that could be inflammatory markers in TMD cases. It is essential to detect TMD risk factors that can predispose subjects to develop TMD or aggravate this disorder. It is necessary to develop a more specific treatment to reduce or eliminate pain and promote a better quality of life for these patients.

It is also important to conduct tests that assess the psychological status and somatosensory profiles of TMD patients, because these assessments can show different effects in patients' pain profile; consequently, they could contribute to understanding the pain mechanism, its maintenance, and treatment guidelines.²³

An investigation demonstrated that centrally mediated myalgia and TMD with disc displacement had higher pain intensity than masticatory myofascial pain, local myalgia, capsulitis/synovitis, and continuous neuropathic pain, which could be explained by genetic, psychological, social, or behavioral aspects.³⁰ Elevated levels of TNF- α and its -308G/A polymorphism, which is associated with higher concentrations of this interleukin,^{13,24} could be present in patients with greater pain intensity.

The limitations of the studies analyzed in this review were the small sample sizes considered in some studies, different diagnostic criteria, and the fact that while some studies involved both women and men, some control groups consisted only of men. It is essential to follow the same diagnostic criteria, taxonomy, and nomenclature, because research questions and findings can be standardized; consequently, clinicians can better diagnose and monitor their patients.⁵ Few studies have evaluated the TNF- α profile in patients with TMD. Our suggestion for similar studies in future is to work with larger sample sizes that have also women constituting the control group, because TMD is more severe in women.³ In addition, these studies analyzed interleukin levels in different fluid samples, like synovial fluid and blood, which makes it difficult to compare the articles. We suggest that TNF- α levels and the analyzed polymorphism can be used as inflammatory markers for developing a more targeted treatment protocol.

CONCLUSION

Most TMD patients showed a predisposition to a greater production of TNF- α , which could be explained by the presence of the -308G/A polymorphism. Further investigations are required to confirm the results of this review and to analyze the role of other proinflammatory and anti-inflammatory interleukins and their polymorphisms in TMD.

AUTHORS' CONTRIBUTIONS

Camilla Porto Campello (CPC)

Elker Lene Santos de Lima (ELSL)

Renata Silva Melo Fernandes (RSMF)

Mirza Porto (MP)

Maria Tereza Cartaxo Muniz (MTCM)

Conception or design of the study:

CPC, RSMF.

Data acquisition, analysis or interpretation:

CPC, ELSL, RSMF, MP, MTCM.

Writing the article:

CPC, RSMF.

Critical revision of the article:

CPC, ELSL, RSMF, MP, MTCM.

Final approval of the article:

CPC, ELSL, RSMF, MP, MTCM.

Overall responsibility:

MTCM.

The authors report no commercial, proprietary or financial interest in the products or companies described in this article.

REFERENCES

1. Câmara-Souza MB, Figueredo OMC, Maia PRL, Dantas IS, Barbosa GAS. Cervical posture analysis in dental students and its correlation with temporomandibular disorder. *Cranio*. 2018 Mar;36(2):85-90.
2. National Institute of Dental and Craniofacial Research Data & Statistics. Facial pain. [acesso 28 nov 2019]. Disponível em: <https://www.nidcr.nih.gov/research/data-statistics/facial-pain>.
3. Staniszewski K, Lygre H, Bifulco E, Kvinnsland S, Willassen L, Helgeland E, et al. Temporomandibular disorders related to stress and HPA-Axis regulation. *Pain Res Manag*. 2018 May 2;2018:7020751.
4. Freitas LV, Lopes AC, Piatto VB, Maniglia JV. Association of temporomandibular dysfunction with the 102T-C polymorphism in the serotonin receptor gene in Brazilian patients. *Arch Med Sci*. 2013 Dec 30;9(6):1013-8.
5. Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet JP, et al. Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: recommendations of the International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Group†. *J Oral Facial Pain Headache*. 2014 Winter;28(1):6-27.
6. Smith SB, Maixner DW, Greenspan JD, Dubner R, Fillingim RB, Ohrbach R, et al. Potential genetic risk factors for chronic TMD: genetic associations from the OPPERA case control study. *J Pain*. 2011 Nov;12(11 Suppl): T92-101.

7. Wieckiewicz M, Boening K, Wiland P, Shiau YY, Paradowska-Stolarz A. Reported concepts for the treatment modalities and pain management of temporomandibular disorders. *J Headache Pain*. 2015;16:106.
8. Mor N, Tang C, Blitzer A. Temporomandibular myofacial pain treated with botulinum toxin injection. *Toxins (Basel)*. 2015 Jul 24;7(8):2791-800.
9. Machado BC, Mazzetto MO, Da Silva MA, de Felício CM. Effects of oral motor exercises and laser therapy on chronic temporomandibular disorders: a randomized study with follow-up. *Lasers Med Sci*. 2016 Jul;31(5):945-54.
10. Patel MH, Kim RY, Aronovich S, Skouteris CA. Clinical assessment of acellular dermal matrix (AlloDerm©) as an option in the replacement of the temporomandibular joint disc: a pilot study. *J Stomatol Oral Maxillofac Surg*. 2020 Nov;121(5):496-500.
11. Yang ZC, Xu F, Tang M, Xiong X. Association between TNF- α Promoter -308 A/G polymorphism and systemic lupus erythematosus susceptibility: a case-control study and meta-analysis. *Scand J Immunol*. 2017 Mar;85(3):197-210.
12. Lin Y, Wang L, Yan Y, Zhou W, Chen Z. A meta-analysis of tumor necrosis factor- α and FAS/FASL polymorphisms with risk of pre-eclampsia. *Hypertens Pregnancy*. 2019 Feb;38(1):20-31.
13. Zhang M, Peng LL, Ji XL, Yang HB, Zha RS, Gui GP. Tumor necrosis factor gene polymorphisms are associated with silicosis: a systemic review and meta-analysis. *Biosci Rep*. 2019 Feb;39(2):BSR20181896.

14. Mezones-Holguin E, Gamboa-Cardenas RV, Sanchez-Felix G, Chávez-Corrales J, Helguero-Santin LM, Laban Seminario LM, et al. Efficacy and safety in the continued treatment with a biosimilar drug in patients receiving infliximab: a systematic review in the context of decision-making from a Latin-American Country. *Front Pharmacol*. 2019 Nov 15;10:1010.
15. Takahashi T, Kondoh T, Fukuda M, Yamazaki Y, Toyosaki T, Suzuki R. Proinflammatory cytokines detectable in synovial fluids from patients with temporomandibular disorders. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 1998 Feb;85(2):135-41.
16. Kaneyama K, Segami N, Nishimura M, Suzuki T, Sato J. Importance of proinflammatory cytokines in synovial fluid from 121 joints with temporomandibular disorders. *Br J Oral Maxillofac Surg*. 2002 Oct;40(5):418-23.
17. Lee JK, Cho YS, Song SI. Relationship of synovial tumor necrosis factor alpha and interleukin 6 to temporomandibular disorder. *J Oral Maxillofac Surg*. 2010 May;68(5):1064-8.
18. Park JW, Chung JW. Inflammatory cytokines and sleep disturbance in patients with temporomandibular disorders. *J Oral Facial Pain Headache*. 2016 Winter;30(1):27-33.
19. Louca Jounger S, Christidis N, Svensson P, List T, Ernberg M. Increased levels of intramuscular cytokines in patients with jaw muscle pain. *J Headache Pain*. 2017 Dec;18(1):30.

20. Furquim BD, Flamengui LM, Repeke CE, Cavalla F, Garlet GP, Conti PC. Influence of TNF- α -308 G/A gene polymorphism on temporomandibular disorder. *Am J Orthod Dentofacial Orthop.* 2016 May;149(5):692-8.
21. Dworkin SF, LeResche L. Research diagnostic criteria for temporomandibular disorders: review, criteria, examinations and specifications, critique. *J Craniomandib Disord.* 1992 Fall;6(4):301-55.
22. Graue AM, Jokstad A, Assmus J, Skeie MS. Prevalence among adolescents in Bergen, Western Norway, of temporomandibular disorders according to the DC/TMD criteria and examination protocol. *Acta Odontol Scand.* 2016 Aug;74(6):449-55.
23. Araújo Oliveira Ferreira DM, Costa YM, de Quevedo HM, Bonjardim LR, Rodrigues Conti PC. Experimental psychological stress on quantitative sensory testing response in patients with temporomandibular disorders. *J Oral Facial Pain Headache.* 2018 Fall;32(4):428-35.
24. Fernandes H, Koneru B, Fernandes N, Hameed M, Cohen MC, Raveche E, et al. Investigation of promoter polymorphisms in the tumor necrosis factor-alpha and interleukin-10 genes in liver transplant patients. *Transplantation.* 2002 Jun 27;73(12):1886-91.
25. Dobsak T, Heimel P, Tangl S, Schwarze UY, Schett G, Gruber R. Impaired periodontium and temporomandibular joints in tumour necrosis factor- α transgenic mice. *J Clin Periodontol.* 2017 Dec;44(12):1226-35.

26. Wilentz JB, Cowley AW Jr. How can precision medicine be applied to temporomandibular disorders and its comorbidities? *Mol Pain*. 2017 Jan-Dec;13:1744806917710094.
27. Ibi M. Inflammation and temporomandibular joint derangement. *Biol Pharm Bull*. 2019;42(4):538-42.
28. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. *Health Technol Assess* 2006 Nov;10(42):iii-iv, xi-xiii, 1-229.
29. Cordeiro PC, Guimaraes JP, de Souza VA, Dias IM, Silva JN, Devito KL, et al. Temporomandibular joint involvement in rheumatoid arthritis patients: association between clinical and tomographic data. *Acta Odontol Latinoam*. 2016 Dec;29(3):123-9.
30. Boggero IA, Rojas-Ramirez MV, de Leeuw R, Carlson CR. Satisfaction with Life in Orofacial Pain Disorders: Associations and Theoretical Implications. *J Oral Facial Pain Headache*. 2016 Spring;30(2):99-106.